Cidara Therapeutics price target raised to $47 from $46 at Citizens JMP

Citizens JMP raised the firm’s price target on Cidara Therapeutics (CDTX) to $47 from $46 and keeps an Outperform rating on the shares. Citizens remains confident in a positive readout in late July, and expects robust drug exposure as well as background infection rates, the analyst tells investors in a research note.